56例初治多发性骨髓瘤患者接受PAD联合治疗的疗效及预后 - Suppr

Suppr

超能文献

[Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma].

作者信息

Yan S, Fu C C, Ma L, Zhou J, Jin S, Yan L Z, Zhu X M, Wang P F, Xu Y, Wu D P

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):520-2. doi: 10.3760/cma.j.issn.0253-2727.2016.06.016.

DOI:10.3760/cma.j.issn.0253-2727.2016.06.016

PMID:27431080

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7348346/

Abstract

摘要

相似文献

[Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma].

Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):520-2. doi: 10.3760/cma.j.issn.0253-2727.2016.06.016.

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.

Br J Haematol. 2022 Feb;196(4):e33-e37. doi: 10.1111/bjh.17903. Epub 2021 Oct 11.

[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].

Zhonghua Nei Ke Za Zhi. 2016 Sep 1;55(9):689-94. doi: 10.3760/cma.j.issn.0578-1426.2016.09.007.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.

[Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone].

Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):463. doi: 10.3760/cma.j.issn.0253-2727.2016.06.004.

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Br J Haematol. 2005 Jun;129(6):755-62. doi: 10.1111/j.1365-2141.2005.05519.x.

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.

Intern Med. 2016;55(20):3025-3028. doi: 10.2169/internalmedicine.55.6470. Epub 2016 Oct 15.

Optimizing therapy in bortezomib-exposed patients with multiple myeloma.

Expert Rev Hematol. 2018 Jun;11(6):463-469. doi: 10.1080/17474086.2018.1479637. Epub 2018 May 28.

A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.

Ann Hematol. 2011 Feb;90(2):193-200. doi: 10.1007/s00277-010-1052-8. Epub 2010 Sep 1.

本文引用的文献

Where we were, where we are, where we are going: progress in multiple myeloma.

Am Soc Clin Oncol Educ Book. 2014:199-203. doi: 10.14694/EdBook_AM.2014.34.199.

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Haematologica. 2014 Feb;99(2):353-9. doi: 10.3324/haematol.2013.088211. Epub 2013 Nov 8.

[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma].

Zhonghua Xue Ye Xue Za Zhi. 2013 Oct;34(10):868-72. doi: 10.3760/cma.j.issn.0253-2727.2013.10.009.

IMWG consensus on risk stratification in multiple myeloma.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.

Br J Haematol. 2008 May;141(4):512-6. doi: 10.1111/j.1365-2141.2008.06997.x. Epub 2008 Mar 26.

Multiple myeloma.

Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.

Role of genetics in prognostication in myeloma.

Best Pract Res Clin Haematol. 2007 Dec;20(4):625-35. doi: 10.1016/j.beha.2007.08.005.

Improved survival in multiple myeloma and the impact of novel therapies.

Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Br J Haematol. 2005 Jun;129(6):755-62. doi: 10.1111/j.1365-2141.2005.05519.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验